Entry Detail



General Information

Database ID:TRD05301
Confidence:High
Contents:>> tsRNA Information
>> tsRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference



tsRNA Information

tsRNA Name:AS-tDR-011363
tsRNA Type:N/A
Amino acid and Anticodon:N/A
Sequence:N/A
Related Target:N/A
Predicted Target:N/A
External Links:
MINTbase ID:N/A
tRFdb ID:N/A



tsRNA Association Statistics

Total Associated Disease Number:5
More Information
Network:
(Display the first 15 nodes)



Disease Information

 MeSHDisease Ontology
Disease ID:D009072DOID:13099
Disease Name:Moyamoya diseaseMoyamoya disease
Category:MeSHDisease Ontology
Type:Nervous System Diseases//Cardiovascular Diseasesdisease of anatomical entity//nervous system disease
Define:A noninflammatory, progressive occlusion of the intracranial CAROTID ARTERIES and the formation of netlike collateral arteries arising from the CIRCLE OF WILLIS. Cerebral angiogram shows the puff-of-smoke (moyamoya) collaterals at the base of the brain. It is characterized by endothelial HYPERPLASIA and FIBROSIS with thickening of arterial walls. This disease primarily affects children but can also occur in adults.A cerebral arterial disease characterized by constriction of certain arteries at the base of the brain. Blood flow is blocked by the constriction and also by blood clots.
Alias:Cerebrovascular Moyamoya Disease//Moya-Moya Disease//Moyamoya Disease, Classic//Moyamoya Disease, Primary//Moyamoya Disease, Secondary//Moyamoya Syndrome//Progressive Intracranial Occlusive Arteropathy (Moyamoya)progressive intracranial arterial occlusion



Disease Association Statistics

Total Associated tsRNA Number:20
More Information
Network:
(Display the first 15 nodes)



Evidence Support

Strong Evidence:RT-PCR
Weak Evidence:High-throughput sequencing



Reference

[1] PubMed ID:30896793
Disease Name:Moyamoya disease
Tissue:Vessel
Dysfunction Pattern:Up-Regulation
Validated Method:RT-PCR//High-throughput sequencing
Description:The sequencing results demonstrated that 38 tRFs were differentially expressed between patients and controls, of which 22 were upregulated and 16 were downregulated. RT-qPCR analysis confirmed the validity of the sequencing results. GO and KEGG pathway enrichment analyses indicated that 18 pathways were associated with the selected tRFs. These pathways were mainly involved in angiogenesis and metabolism, both of which are physiopathological fundamentals of MMD. The results provided a novel insight into the mechanisms underlying MMD pathogenesis, and demonstrated that tRFs may serve as potential therapeutic targets for the future treatment of MMD.
Comparision:Disease VS Control
Mechanism:N/A